Accelerate the clinical development to benefit CLL/SLL patients.
Excited to announce the IND approval to conduct the clinical trial of BCL2 inhibitor ICP-248 in combination with BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. https://lnkd.in/ewtphwAE
